How do common chronic conditions affect health-related quality of life?

Isobel TM Heyworth, Michelle L Hazell, Mary F Linehan and Timothy L Frank

ABSTRACT

Background

Comorbidity is common. National Institute for Health and Clinical Excellence (NICE) guidelines have been created to make best use of resources to improve patients’ quality of life but do not currently take account of comorbidity. The effect of multiple chronic conditions with regard to health-related quality of life (HRQoL) is poorly researched. Criticisms of previous research have been due to patient-defined chronic conditions, lack of quantification of the effects of confounding factors, selection of affected patients only, small sample sizes, and upper age limits.

Aim

This study aims to address these issues, looking into the impact of combinations of chronic conditions on HRQoL.

Design of the study

Participants filled in a questionnaire containing general health information, specific respiratory questions, and the EQ-5D measure of HRQoL. The questionnaires were then matched up to their GP records to obtain their disease status for six common chronic diseases (asthma, chronic obstructive pulmonary disease, ischaemic heart disease, hypertension, diabetes, and cerebrovascular disease).

Method

Data from a mailed questionnaire were analysed from 5169 patients aged >16 years from two general practices in Wythenshawe, Manchester in 2004. Completion of the questionnaire was taken to indicate consent to participate.

Results

Significant correlations were found between a lower HRQoL and increasing numbers of chronic conditions (P<0.001), increasing age, possible obstructive airway disease, lack of higher education, smoking, and female sex. These all remained significant following regression, except for sex, with number of chronic conditions being a strong predictor of the weighted health state index score, EQ-SD-wtd (coefficient = -0.079, P<0.001).

Conclusion

Increasing numbers of chronic conditions have a strong negative effect on HRQoL.

Keywords

chronic disease; comorbidity; EQ-SD; health related quality of life.

INTRODUCTION

Improvements in living conditions, together with advances in medical science, have led to an increased number of patients living with chronic conditions. Studies indicate that comorbidity is the normal state of affairs, especially in patients aged >65 years, and 50% of patients with a chronic disease have more than one. Within the UK healthcare system, there has therefore been a shift in the way in which patients are treated, evidenced by the Department of Health recognising the importance of long-term conditions, and by The Royal College of General Practitioners including the ability to provide person-centered care as a core competence for GPs. This, in addition to numerous choices in treatments and the limitations of a publicly funded health service, has made quality of life measurement a hugely relevant issue in 2009.

Priorities in health care must be set, and it is now generally accepted that one of the most important considerations should be the improvement in patients’ health-related quality of life (HRQoL) with a treatment, rather than relying solely on change measured from the healthcare professional’s perspective. A single HRQoL value in conjunction with cost and distribution issues could be key to choosing...
How this fits in
This paper adds information collected from a primary care setting relating to how health-related quality of life is adversely affected by increasing numbers of chronic conditions.

METHOD
In the UK, patients register with one GP in order to access NHS facilities. Practices keep records of consultations, diagnoses, and prescriptions and these records go with a patient if they move to another practice. All patients registered with either of two general practices were invited to take part in a postal survey in 2004. The survey asked about specific respiratory problems as well as general health details, and included the EQ-5D questionnaire about HRQoL.

Statistical analysis was conducted using the computer software program SPSS (version 15, SPSS Inc, 2006). χ² values were calculated for the exploration of differences in proportions, Student t-tests for differences in HRQoL means, and linear regression analysis to correct for confounding factors. Values of $P<0.05$ were taken to indicate statistical significance.

RESULTS
Participation
Of the 11 020 individuals included in the postal survey, 5169 (46.9%) responded, and of these 333 (6.4%) opted out of the matching with medical records data that followed. Statistical analyses were conducted to check that these opt outs were not a distinct group that would consequently be under-represented within the data. The results showed that overall there was no difference between opt outs and those included in the main analyses with regard to sex, smoking, or passive smoking (Table 1). There were, however, several differences that built up an interesting picture of the people more likely to opt out.

Despite this advancement in measuring quality of life, research has poorly represented combinations of chronic conditions. The papers that do exist have tended to focus on a single chronic disease, for example chronic obstructive pulmonary disease (COPD) or diabetes, yet practical observation indicates that such patients often suffer with multiple problems. Even the existing and widely used reference values for EQ-5D in the UK do not currently take account of comorbidity. Fortin et al concluded in 2005 that, to date, the number and diversity of articles on comorbidity are both insufficient to provide scientific background for strong evidence-based care of patients affected by multiple concurrent chronic conditions, and that the deficit in research is particularly marked within the primary care setting.

This paper addresses this gap in knowledge by examining the impact of the combinations of common chronic conditions on HRQoL.
Table 1. Characteristics of individuals by decision to opt out of disease register analyses with significance levels for t-tests of differences in means and \( \chi^2 \) tests of differences in proportions.

<table>
<thead>
<tr>
<th></th>
<th>Opted out (n = 333)</th>
<th>Opted in (n = 4836)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (SD)</td>
<td>50.9 (20.2)</td>
<td>47.9 (21.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female, % (n)</td>
<td>59.5 (194/326)</td>
<td>54.9 (2595/4729)</td>
<td>0.100</td>
</tr>
<tr>
<td>Smokers, % (n)</td>
<td>36.4 (91/250)</td>
<td>37.6 (1402/3727)</td>
<td>0.700</td>
</tr>
<tr>
<td>Exposed to passive smoke at home, % (n)</td>
<td>35.7 (85/238)</td>
<td>38.5 (1440/3738)</td>
<td>0.390</td>
</tr>
<tr>
<td>Higher education, % (n)</td>
<td>28.9 (95/329)</td>
<td>37.7 (1801/4773)</td>
<td>0.001</td>
</tr>
<tr>
<td>Seeking work, % (n)</td>
<td>3.8 (12/316)</td>
<td>2.3 (103/4558)</td>
<td>0.080</td>
</tr>
<tr>
<td>EQ-5D problems, % (n) :</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobility</td>
<td>29.7 (94/316)</td>
<td>31.3 (1478/4722)</td>
<td>0.560</td>
</tr>
<tr>
<td>Self-care</td>
<td>14.3 (45/314)</td>
<td>12.5 (583/4658)</td>
<td>0.350</td>
</tr>
<tr>
<td>Usual activities</td>
<td>31.8 (101/318)</td>
<td>31.0 (1461/4717)</td>
<td>0.770</td>
</tr>
<tr>
<td>Pain/discomfort</td>
<td>46.4 (148/319)</td>
<td>47.5 (2231/4695)</td>
<td>0.700</td>
</tr>
<tr>
<td>Anxiety/depression</td>
<td>42.4 (133/314)</td>
<td>35.2 (1642/4671)</td>
<td>0.010</td>
</tr>
<tr>
<td>EQ-5D(_{mean}), mean (SD)</td>
<td>0.8 (0.3)</td>
<td>0.8 (0.3)</td>
<td>0.940</td>
</tr>
<tr>
<td>EQ-5D(_{mean}), mean (SD)</td>
<td>73.8 (19.8)</td>
<td>70.9 (19.8)</td>
<td>0.010</td>
</tr>
</tbody>
</table>

Table 2. Characteristics of chronic disease groups within the study.

<table>
<thead>
<tr>
<th></th>
<th>Asthma (n = 429)</th>
<th>COPD (n = 280)</th>
<th>Diabetes (n = 348)</th>
<th>Hypertension (n = 1201)</th>
<th>IHD (n = 442)</th>
<th>Stroke (n = 101)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% those who had &gt;1 chronic disease (n = 1902)</td>
<td>22.6</td>
<td>14.7</td>
<td>18.3</td>
<td>63.1</td>
<td>23.2</td>
<td>5.3</td>
</tr>
<tr>
<td>% questionnaire responders (n = 5169)</td>
<td>8.3</td>
<td>5.4</td>
<td>6.7</td>
<td>23.2</td>
<td>8.6</td>
<td>2.0</td>
</tr>
<tr>
<td>EQ-5D(_{mean}), mean (SD)</td>
<td>0.67 (0.34)</td>
<td>0.53 (0.35)</td>
<td>0.62 (0.34)</td>
<td>0.65 (0.32)</td>
<td>0.55 (0.34)</td>
<td>0.49 (0.36)</td>
</tr>
<tr>
<td>EQ-5D(_{mean}), mean (SD)</td>
<td>65.5 (22.3)</td>
<td>57.5 (19.8)</td>
<td>63.8 (20.4)</td>
<td>67.1 (19.8)</td>
<td>61.0 (20.0)</td>
<td>57.4 (21.3)</td>
</tr>
</tbody>
</table>

COPD = chronic obstructive pulmonary disease. IHD = ischaemic heart disease.

Individuals who opted out were older (mean (standard deviation, [SD]) age 50.9 years (20.2) versus 47.9 (21.2) years, P<0.001) and significantly less likely to have higher education than those who opted in (28.9% [95] versus 37.7% [1801, P for \( \chi^2 \) test = 0.001]). They were also more likely to have reported problems on the anxiety/depression domain of the EQ-5D (42.4% [133] versus 35.2% [1646], P = 0.011), but all the other domain questions showed equality between the two groups (Table 1). EQ-5D\(_{mean}\) showed no significant difference between the groups; however, people who opted out had a significantly lower EQ-5D\(_{mean}\) value (mean [SD] of 70.9 years [19.8] compared to 73.8 years [19.8], P = 0.014) (Table 1).

Main analyses

The main analyses showed that hypertension was by far the highest represented chronic condition as well as having the highest EQ-5D\(_{mean}\)/EQ-5D\(_{mean}\) results (Table 2). The least common chronic condition was stroke, while the lowest EQ-5D\(_{mean}\)/EQ-5D\(_{mean}\) values were seen in COPD (Table 2).

A decrease in EQ-5D\(_{mean}\) and EQ-5D\(_{mean}\) with age was highly significant (P<0.001) in the study results (Pearson correlation coefficient = -0.33 for EQ-5D\(_{mean}\) and -0.29 for EQ-5D\(_{mean}\)). Significantly lower values of HRQoL on both EQ-5D\(_{mean}\) and EQ-5D\(_{mean}\) were associated with female sex, smoking, and absence of higher education. Higher education showed the greatest impact. No significant difference was seen with passive smoke exposure (responder reports of other adults in the home who smoke) (Table 3).

The values for EQ-5D\(_{mean}\) and EQ-5D\(_{mean}\) showed a highly significant (P<0.001) decrease with increasing number of chronic conditions (Spearman rank correlation coefficient for EQ-5D\(_{mean}\) and -0.342 and for EQ-5D\(_{mean}\) = -0.332). There appeared to be a consistent decrease in quality of life value with each added chronic disease (Table 4 and Figures 1 and 2).

A stepwise linear regression analysis of number of chronic conditions, age, sex, smoking status, and continued education (probability to enter, <0.05; probability to remove, >0.1), with EQ-5D\(_{mean}\)/EQ-5D\(_{mean}\) as the dependent variable, identified that this correlation was still significant following the consideration of confounding factors (P<0.001). It also demonstrated that the total number of chronic conditions was an important factor in relation to both EQ-5D\(_{mean}\) and EQ-5D\(_{mean}\) (coefficients = -0.079, P<0.001 and -5.914, P<0.001 respectively), although smoking was associated with the largest effects (Table 5). Breaking down the EQ-5D\(_{mean}\) into its component dimensions showed that problems in all five dimensions became more common with increasing numbers of chronic conditions (Table 6).
**DISCUSSION**

**Summary of main findings**

The study results show that HRQoL declined significantly and consistently with an increasing number of chronic conditions and that this decline persisted following correction for confounding factors. The comparatively small number of studies that have also looked into the issue seem to support this observation, although there are some differences. Wee et al demonstrated that individuals with diabetes had a decreasing HRQoL with comorbid hypertension, heart disease, or musculoskeletal illness. Their study did, however, also show an increasing and synergistic HRQoL value with comorbid heart disease. Fortin et al showed that chronic vascular, upper gastrointestinal and musculoskeletal conditions also correlated with a drop in HRQoL, including a synergistic negative effect between respiratory and cardiac complaints. This previously reported link, thought to be due to inflammatory markers, might go some way to explaining the effects of COPD seen in the present study.

**Strengths and limitations of the study**

Generally, current research supports the negative correlation between number of chronic conditions and HRQoL. No direct comparisons can be made due to the extremely small number of studies and lack of comparable methods. As the present study used healthcare professionals’ determination of chronic condition status, it is of considerable interest within a field that is often criticised for using patient-determined chronic condition status. GPs are more likely than patients to use standardised diagnostic criteria, making the results more accurate. It avoids other criticisms by having a comparatively large sample size and correcting for confounding factors, and represents both healthy and affected individuals with no upper age limit.

It is important to point out, however, that within the study sample, numbers of patients with each added disease dwindled to just four patients with five chronic conditions, and there were no patients with the full six conditions. Nevertheless, this link between HRQoL and number of chronic conditions has not been widely observed before and has implications for clinical practice.

Factors influencing the decision to opt out among the study sample must be considered. Absence of higher education might be associated with a lack of awareness as to what research may entail, and the reporting of anxiety and depression might be linked to it.

**Table 4. Health-related quality of life by number of chronic diseases.**

<table>
<thead>
<tr>
<th>Chronic diseases, n</th>
<th>Individuals, n</th>
<th>EQ-SDmax Mean (SD)</th>
<th>95% CI</th>
<th>EQ-SDmax Mean (SD)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2934</td>
<td>0.83 (0.25)</td>
<td>0.82 to 0.84</td>
<td>78.6 (17.9)</td>
<td>77.9 to 79.3</td>
</tr>
<tr>
<td>1</td>
<td>1209</td>
<td>0.69 (0.32)</td>
<td>0.67 to 0.71</td>
<td>69.4 (19.7)</td>
<td>68.2 to 70.6</td>
</tr>
<tr>
<td>2</td>
<td>510</td>
<td>0.61 (0.33)</td>
<td>0.58 to 0.64</td>
<td>63.3 (19.0)</td>
<td>61.6 to 65.0</td>
</tr>
<tr>
<td>3</td>
<td>164</td>
<td>0.50 (0.37)</td>
<td>0.44 to 0.56</td>
<td>56.7 (21.9)</td>
<td>53.2 to 60.3</td>
</tr>
<tr>
<td>4</td>
<td>15</td>
<td>0.39 (0.32)</td>
<td>0.22 to 0.57</td>
<td>40.7 (16.6)</td>
<td>30.2 to 51.1</td>
</tr>
<tr>
<td>5</td>
<td>4</td>
<td>0.25 (0.36)</td>
<td>–0.33 to 0.83</td>
<td>39.2 (7.0)</td>
<td>28.1 to 50.4</td>
</tr>
</tbody>
</table>

**Figure 1. Graph to show mean EQ-SDmax with increasing number of chronic conditions.**

**Figure 2. Graph to show mean EQ-SD with increasing number of chronic conditions.**

---

*British Journal of General Practice, November 2009*
nervousness about the consequences in use of medical records leading to a decision to opt out. Overall, the analysis of this group suggests minimal impact on the present study by those who opted out. The small differences could mean that older, less educated, and anxious or depressed patients are slightly less well represented within the study data, causing a small overestimate of the HRQoL values, since all these groups were shown to be more likely to have a lower HRQoL, both here and in previous studies.²⁷,²⁸

The corroboration of previously reported correlations regarding age,²⁵,²⁷ sex,²⁹–³² smoking status,²⁸,²⁹ and higher education³³ are important not only to back up previous research, but also to validate the ability of the present results to represent the general population sample. However, although the differences are significant, the effect sizes are small and must be viewed within the context of the minimal important differences for EQ-5D₃₀ and EQ-5D₅₀, which are as yet not fully determined.

Comparison with existing literature

The finding of significant difference between those who had a higher education compared to those who did not is not consistently demonstrated. While the population of the present study was taken from an area in South Manchester designated as deprived,³¹ which might be thought to maximise any potential difference, it is worth noting that previous studies in the same area of Manchester have shown mixed effects.³¹ Studies elsewhere, however, have supported this finding; in an 8-year longitudinal study in Chicago, US, Browning et al found that when income and education were examined, HRQoL improved in relation to reported improvement in education and income.²⁵ Browning, et al did not, however, find an association between unemployment and poor HRQoL.²⁰ This mixed effect might be somewhat explained by the presence of higher education being tied up with other confounding factors; such as financial status, background, or available resources. This seems to be supported by the present study results following regression analysis.

The only factor that lost significance following regression was sex. Since this study had no upper age limit, including a patient aged 100 years old, this may be because the apparent sex difference was in fact an age difference caused by the increased life expectancy of women.

The EQ-5D₃₀ dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression all showed a consistent negative relationship with increasing number of chronic conditions, explaining the observed trend in EQ-5D₃₀. Each extra condition has an impact on a patient’s functions independent of other conditions, but causes a cumulative effect on EQ-5D₃₀.

Previous papers have found that HRQoL is closely linked to physical ability²³,³⁴ and depression.²⁵ This study’s breakdown of the EQ-5D dimensions supports these claims but finds their impact to be roughly equal, again supporting calls to treat individuals holistically.

Implications for future research and clinical practice

Despite the widespread use of the EQ-5D₃₀ by NICE to aid economic decision making in the UK, the impact of multiple chronic conditions is frequently not considered. This study provides evidence that comorbidity is an important covariate of HRQoL as measured by the EQ-5D. However, it does not distinguish between the different combinations of chronic conditions and is naturally weighted towards those that are more common (for example,
hypertension and asthma). Is it worse to have two difficult-to-treat, severely disabling diseases or four milder conditions that can be better controlled? Which diseases are worse in combination? It is known that models of health promotion, specifically for those with long-term disabilities have recognised the importance of the physical, cultural, and economic environment. So what are the effects of the other confounding factors such as social support, educational background, and economic status? In addition, combinations and duration of conditions, including co-existing acute conditions, need to be considered. It is hoped that in so doing, an increasingly holistic approach to patient care and equitable resource allocation decisions can be made.

Funding body

Funding to conduct the analyses presented here was provided by the Small Research Grants Scheme of Manchester PCT. The WYCAP surveys were funded by grants from the NHS Executive (RDO/28/1/01), Allen and Hanbury’s, Manchester Airport, GlaxoSmithKline, and Astra Zeneca. None of the funding bodies had any involvement in the data collection, analysis, or interpretation, the preparation of manuscripts or the decision to submit for publication.

Ethical approval

Ethical approval for the 1999 survey was obtained from the Local Research Ethics Committee. The 2001 and 2004 surveys were approved by South Manchester Local Research Ethics Committee and Oldham Local Research Ethics Committee respectively.

Competing interests

Isobel TM Heyworth has no competing interests to declare. Mary F Linehan has received travel grants from GSK. Michelle L Hazell has received a fee from Boehringer Ingelheim for speaking and travel grants from GSK, Boehringer Ingelheim and MSD. Timothy L Frank has received fees for speaking from GSK, Boehringer Ingelheim, Schering Plough, Pfizer, and Astra Zeneca; funds for research from GSK, Boehringer Ingelheim, MSD and Schering Plough; funds for consultancy from GSK, Chiesi Pharmaceuticals, and Pharmaia, and travel grants from GSK, Boehringer Ingelheim, Astra Zeneca, Chiesi Pharmaceuticals, and MSD.

Discuss this article

Contribute and read comments about this article on the Discussion Forum: http://www.rcgp.org.uk/bjgp-discuss

REFERENCES